Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
Protocol ID
MK-7902-013
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapsed/refractory
Location
NSW, QLD, VIC, WA, NZ
Sponsor
Merck Sharp & Dohme Corp.
Collaborators
Eisai Inc.
Trial Status
Open
Sites
Perth Children's Hospital
Royal Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
2 Years to 21 Years
International registry ID's
NCT04447755
Back to Registry
Study Title An Open-Label Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children Adolescents and Young Adults with Relapsed or Refractory Solid Malignancies
Protocol ID MK-7902-013
Disease (Sub Disease) Solid tumours
Diagnosis Stage Relapsed/refractory
Location NSW / QLD / VIC / WA / NZ
Sponsor Merck Sharp & Dohme Corp.
Collaborators Eisai Inc.
Links https://clinicaltrials.gov/ct2/show/NCT04447755
Trial Status Open
Trial Open Date 30/07/2020
Sites Perth Children's Hospital / Royal Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Starship Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 2 Years to 21 Years
International registry ID's NCT04447755